However, the European Society of Cardiology has recently updated the AHF guideline, highlighting the STRONG-HF clinical trial, which has demonstrated the efficacy of early introduction of oral therapy for HF, including Angiotensin-converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs), BBs, and mineralocorticoid receptor antagonists, around 2 days before hospital discharge. The gene discussed is NR3C2; the disease is hydrops fetalis.